Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) have been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $13.80.

OBIO has been the subject of several analyst reports. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Orchestra BioMed in a research note on Thursday, November 13th. TD Cowen initiated coverage on shares of Orchestra BioMed in a report on Wednesday, December 10th. They issued a “buy” rating for the company. Finally, Barclays lifted their price objective on Orchestra BioMed from $11.00 to $12.00 and gave the stock an “overweight” rating in a report on Friday, January 9th.

Orchestra BioMed Stock Performance

NASDAQ:OBIO opened at $3.92 on Friday. The firm has a 50 day simple moving average of $4.16 and a 200-day simple moving average of $3.66. Orchestra BioMed has a 1-year low of $2.20 and a 1-year high of $5.42. The firm has a market cap of $221.34 million, a PE ratio of -2.15 and a beta of 0.61. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.73 and a quick ratio of 4.72.

Institutional Investors Weigh In On Orchestra BioMed

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alyeska Investment Group L.P. bought a new stake in shares of Orchestra BioMed during the 3rd quarter valued at $3,386,000. Pathstone Holdings LLC acquired a new position in Orchestra BioMed during the third quarter worth $2,495,000. Vanguard Group Inc. increased its position in shares of Orchestra BioMed by 28.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock worth $3,675,000 after purchasing an additional 324,558 shares during the last quarter. 683 Capital Management LLC bought a new stake in shares of Orchestra BioMed in the 4th quarter valued at about $847,000. Finally, Marshall Wace LLP bought a new stake in Orchestra BioMed in the 4th quarter valued at $712,000. Institutional investors and hedge funds own 53.20% of the company’s stock.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.